- Home
- NRIX vs AMC Comparison
NRIX vs AMC Comparison
Compare NRIX & AMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- AMC
- Stock Information
- Founded
- NRIX 2009
- AMC 1920
- Country
- NRIX United States
- AMC United States
- Employees
- NRIX N/A
- AMC N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- AMC Movies/Entertainment
- Sector
- NRIX Health Care
- AMC Consumer Discretionary
- Exchange
- NRIX Nasdaq
- AMC Nasdaq
- Market Cap
- NRIX 1.4B
- AMC 1.5B
- IPO Year
- NRIX 2020
- AMC 2013
- Fundamental
- Price
- NRIX $19.60
- AMC $3.49
- Analyst Decision
- NRIX Strong Buy
- AMC Sell
- Analyst Count
- NRIX 17
- AMC 5
- Target Price
- NRIX $30.29
- AMC $4.30
- AVG Volume (30 Days)
- NRIX 771.6K
- AMC 12.3M
- Earning Date
- NRIX 02-13-2025
- AMC 02-26-2025
- Dividend Yield
- NRIX N/A
- AMC N/A
- EPS Growth
- NRIX N/A
- AMC N/A
- EPS
- NRIX N/A
- AMC N/A
- Revenue
- NRIX $56,424,000.00
- AMC $4,435,200,000.00
- Revenue This Year
- NRIX N/A
- AMC N/A
- Revenue Next Year
- NRIX $3.79
- AMC $11.07
- P/E Ratio
- NRIX N/A
- AMC N/A
- Revenue Growth
- NRIX N/A
- AMC N/A
- 52 Week Low
- NRIX $7.65
- AMC $2.38
- 52 Week High
- NRIX $29.56
- AMC $11.88
- Technical
- Relative Strength Index (RSI)
- NRIX 48.04
- AMC 34.41
- Support Level
- NRIX $18.75
- AMC $3.21
- Resistance Level
- NRIX $20.50
- AMC $3.77
- Average True Range (ATR)
- NRIX 1.08
- AMC 0.19
- MACD
- NRIX 0.18
- AMC -0.03
- Stochastic Oscillator
- NRIX 70.00
- AMC 29.89
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
About AMC AMC Entertainment Holdings Inc.
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. It owns, operates or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, premium presentation. The Company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.